分析左西孟旦治疗重症冠心病并心力衰竭对心肌酶、不良反应及炎症因子的研究  

To Analyse the Effects of Levosimendan on Myocardial Enzymes,Adverse Reactions and Inflammatory Factors in Patients with Severe Coronary Heart Disease and Heart Failure

作　　者：刘永平 王华亭 LIU Yongping;WANG Huating(Department of Cardiology,Jinan Heavy Truck Hospital,Jinan,Shandong Province,250031 China;Department ofCardiology,Jinan Central Hospital Affiliated to Shandong University,Jinan,Shandong Province,250014 China)

机构地区：[1]济南重汽医院心内科,山东济南250031 [2]山东大学附属济南市中心医院心内科,山东济南250014

出　　处：《中外医疗》2022年第32期41-44,共4页China & Foreign Medical Treatment

基　　金：山东省科技计划项目(2009GG20002016)。

摘　　要：目的 分析左西孟旦治疗重症冠心病并心力衰竭对心肌酶、不良反应及炎症因子研究。方法 便利选择2021年1—12月济南重汽医院收治的重症冠心病并心力衰竭患者88例作为研究对象,按随机数表法分为两组,对照组44例采用常规药物治疗,研究组44例采用左西孟旦治疗。比较两组患者NT-proBVVP、心肌酶、心功能、不良反应及炎症因子水平等。结果 研究组患者治疗后NT-proBNP(728.01±88.03)pg/mL、CK-MB(30.30±4.27)U/L、cTnI(0.18±0.05)μg/L均优于对照组,差异有统计学意义(t=26.903、14.388、11.583,P<0.05);研究组患者治疗后LVEF(51.37±2.40)%、LVESD(34.86±1.19)mm优于对照组,差异有统计学意义(t=20.581、18.926,P<0.05);研究组治疗后hs-CRP(3.68±1.13)mg/L、TNF-α(2.94±1.12)ng/mL比对照组低,差异有统计学意义(t=2.798、2.512,P<0.05);研究组血压下降、低钾血症、心率过快等不良反应发生率低于对照组,差异有统计学意义(χ^(2)=8.122,P<0.05)。结论 临床将左西孟旦应用于重症冠心病并心力衰竭患者中,可有效改善患者心衰情况及心功能,降低炎症因子,能减少其不良反应发生。Objective To analyze the effects of levosimendan on myocardial enzymes,adverse reactions and inflamma⁃tory factors in patients with severe coronary heart disease and heart failure.Methods Eighty-eight patients with severe coronary heart disease and heart failure admitted to Jinan Heavy Truck Hospital from January to December 2021 were conveniently selected as the research object and divided into two groups according to the random number table.44 pa⁃tients in the control group were treated with conventional drugs,and 44 patients in the study group were treated with levosimendan.NT-proBNP、Myocardial enzymes,cardiac function adverse reactions and the levels of inflammatory factors were compared between the two groups.Results After treatment,NT-proBNP(728.01±88.03)pg/mL,CK-MB(30.30±4.27)U/L,cTnⅠ(0.18±0.05)μg/L in the study group were better than those in the control group,and the dif⁃ference was statistically significant(t=26.903,14.388,11.583,P<0.05);LVEF(51.37±2.40)%and LVESD(34.86±1.19)mm in the study group were better than those in the control group after treatment,and the difference was statisti⁃cally significant(t=20.581,18.926,P<0.05);hs-CRP(3.68±1.13)mg/L and TNF-α(2.94±1.12)ng/mL in the study group were lower than those in the control group after treatment,and the difference was statistically significant(t=2.798,2.512,P<0.05);the incidence of adverse reactions such as decreased blood pressure,hypokalemia and rapid heart rate in the study group was lower than that in the control group,the difference was statistically significant(χ^(2)=8.122,P<0.05).Conclusion Clinical application of levosimendan in patients with severe coronary heart disease and heart failure can effectively improve heart failure and cardiac function,reduce inflammatory factors,and reduce the oc⁃currence of adverse reactions.

关 键 词：左西孟旦 重症冠心病并心力衰竭 心肌酶 不良反应 炎症因子 

分 类 号：R542[医药卫生—心血管疾病]